Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy

Trial Profile

Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Ixmyelocel-T (Primary)
  • Indications Cardiovascular disorders; Dilated cardiomyopathy; Heart failure
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms CATHETER-DCM
  • Sponsors Aastrom Biosciences
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Jan 2014 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 according to ClinicalTrial.gov record..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top